| Certificates/Standards: | N; |
| Monthly Output: | Not provided |
| Regional: | Not provided |
| Packaging Information: | Not provided |
| Mode Of Payment: | Not provided |
| Delivery Lead Time: | Not provided |
| Main Sales Markets: | North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa |
| Sample Provided: | No |
| Sample Policy: | Not provided |
| Minimum Quantity: | Not provided |
Livaux® is a clinically proven, precision prebiotic derived from New Zealand gold kiwifruit. It selectively nourishes Faecalibacterium prausnitzii (F. prau), a keystone gut bacterium known for its antiinflammatory and other health benefits. Livaux is effective at a low daily dose of 600 mg, making it an ideal ingredient for functional foods and supplements.
Health Outcomes:
• Increases Faecalibacterium prausnitzii Levels: Boosts F. prau abundance by more than one time
• supporting gut health, reducing inflammation, and improving intestinal barrier function.
• Reduces Bloating and Gas: Demonstrated to decrease bloating by up to 47% and reduce hydrogenotrophic bacterial species linked to gas production.
• Improves Bowel Movements: Enhances stool frequency and consistency, with significant improvements in CSBM and BSFS scores over baseline in clinical trials.
• Enhances Probiotic Growth and Stability: Livaux enhances the growth and stability of probiotic strains, increasing their abundance by up to 200% in vitro at a low dose of 25 mg per billion CFU.
• 4 In Vitro Studies: Demonstrate synbiotic benefits.
• 2 Clinical Trials: Published clinical studies show significant Increases F. prau by over 1time in 28 days and improvements in bowel regularity (CSBM) and bloating and other GI symptoms.